These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18219812)

  • 41. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Choice of early and escalation treatment options for multiple sclerosis].
    Linker RA; Kieseier BC
    Nervenarzt; 2008 Oct; 79(10):1123-4,1126-8,1130-2 passim. PubMed ID: 18806985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 44. Contemporary treatment options for relapsing-remitting multiple sclerosis.
    Salhofer-Polanyi S; Leutmezer F
    Drugs Today (Barc); 2014 May; 50(5):365-83. PubMed ID: 24918837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Diagnosis and therapy in multiple sclerosis].
    Sailer M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2010 May; 45(5):328-34. PubMed ID: 20455189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of children with multiple sclerosis.
    Yeh EA
    Paediatr Drugs; 2012 Jun; 14(3):165-77. PubMed ID: 22497553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Current treatment of multiple sclerosis].
    Gout O; Bensa C; Assouad R
    Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon beta-1a in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strategies for managing the side effects of treatments for multiple sclerosis.
    Langer-Gould A; Moses HH; Murray TJ
    Neurology; 2004 Dec; 63(11 Suppl 5):S35-41. PubMed ID: 15596735
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
    Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
    Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 55. Multiple Sclerosis.
    Reich DS; Lucchinetti CF; Calabresi PA
    N Engl J Med; 2018 Jan; 378(2):169-180. PubMed ID: 29320652
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacologic management of multiple sclerosis.
    Blasier MG
    Urol Nurs; 2008 Jun; 28(3):217-9. PubMed ID: 18605517
    [No Abstract]   [Full Text] [Related]  

  • 57. Translational research in neurology and neuroscience 2010: multiple sclerosis.
    Stüve O; Kieseier BC; Hemmer B; Hartung HP; Awad A; Frohman EM; Greenberg BM; Racke MK; Zamvil SS; Phillips JT; Gold R; Chan A; Zettl U; Milo R; Marder E; Khan O; Eagar TN
    Arch Neurol; 2010 Nov; 67(11):1307-15. PubMed ID: 20625066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monoclonal antibodies in the treatment of multiple sclerosis.
    Di Pauli F; Berger T; Reindl M
    Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Considerations in the treatment of relapsing-remitting multiple sclerosis.
    Calabresi PA
    Neurology; 2002 Apr; 58(8 Suppl 4):S10-22. PubMed ID: 11971122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.